Role of Senescence in the Development of Endometrial Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03338985|
Recruitment Status : Recruiting
First Posted : November 9, 2017
Last Update Posted : January 5, 2018
Several molecular studies showed chromosomal alterations in patients with endometrial cancer, with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of interest have been identified (P53, PTEN, PIK3CA, ß-catenin, K-ras ...).
A study has already been carried out at the Reims University Hospital with inclusion of patients with endometrial cancer and patients with endometrial hyperplasia. It identified specific alterations of nosologic continuum of pathology and characterize areas of interest on the genome.
|Condition or disease||Intervention/treatment||Phase|
|Endometrial Hyperplasia and Endometrial Cancers||Genetic: Genetic analysis||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||140 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Role of Senescence in the Development of Endometrial Cancer|
|Actual Study Start Date :||October 16, 2017|
|Estimated Primary Completion Date :||October 16, 2019|
|Estimated Study Completion Date :||April 16, 2020|
Experimental: Group "cases patients"
patients with endometrial hyperplasia or endometrial cancers
Genetic: Genetic analysis
Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
- Genetic imbalances [ Time Frame: Day 0 ]Genetic aberrations detected by comparative genomic hybridization (CGH arry)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03338985
|Contact: Emilie RAIMONDemail@example.com|
|Contact: Emilie RAIMOND firstname.lastname@example.org|